1.Ando K, Suzuki Y, Kaminuma T, Yoshimoto Y, Oike T, Okonogi N, Sato H, Tamaki T, Noda SE, Mimura K, Nakano T. Tumor-specific CD8-positive T cell-mediated antitumor immunity is implicated in the antitumor effect of local hyperthermia. Int J Hyperthermia. 35(1):226-231, 2018.
2.Aoto K, Mimura K, Okayama H, Saito M, Chida S, Noda M, Nakajima T, Saito K, Abe N, Ohki S, Ohtake T, Takenoshita S, Kono K. Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma. Oncol Rep. 39(1): 151-159, 2018.
3.Fujiwara Y, Saito M, Robles AI, Nishida M, Takeshita F, Watanabe M, Ochiya T, Yokota J, Kohno T, Harris CC, Tsuchiya N. A Nucleolar Stress-Specific p53-miR-101 Molecular Circuit Functions as an Intrinsic Tumor-Suppressor Network. EBioMedicine. 33: 33-48, 2018.
4.Kanke Y, Shimomura A, Saito M, Honda T, Shiraishi K, Shimada Y, Watanabe R, Yoshida H, Yoshida M, Shimizu C, Takahashi K, Totsuka H, Ogiwara H, Hirose S, Kono K, Tamura K, Okamoto A, Kinoshita T, Kato T, Kohno T. Gene aberration profile of tumors of adolescent and young adult females. Oncotarget. 29; 9(5): 6228-6237. 2017.
5.Kawamura H, Honda M, Takiguchi K, Kamiga T, Saito K, Yamazaki S, Muto A, Shiraso S, Yamashita N, Iwao T, Saji S, Kono K. Development of a prognostic nomogram for metastatic colorectal cancer patients: The study protocol of a multicenter, retrospective, observational, cohort study. Ann. Cancer Res. Ther. 26(2): 116-119, 2018.
6.Kikuchi D, Saito M, Saito K, Watanabe Y, Matsumoto Y, Kanke Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, Ohki S, Takenoshita S. Upregulated solute carrier family 37 member 1 in colorectal cancer is associated with poor patient outcome and metastasis. Oncol Lett. 15(2): 2065-2072, 2018.
7.Lau WM, Teng E, Huang KK, Tan JW, Das K, Zang Z, Chia T, The M, Kono K, Yong WP, Shabbir A, Tay A, Phua NS, Tan P, Chan SL, So JBY. Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3b. Mol Cancer Ther. 17(1): 232-242, 2018.
8.Lim KS, Mimura K, Kua LF, Shiraishi K, Kono K. Implication of Highly Cytotoxic Natural Killer Cells for Esophageal Squamous Cell Carcinoma Treatment. J Immunother. 41(6): 261-273, 2018.
9.Li Z, Maeda D, Yoshida M, Umakoshi M, Nanjo H, Shiraishi K, Saito M, Kohno T, Konno H, Saito H, Minamiya Y, Goto A. The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer. Lung Cancer. 123: 127-135, 2018.
10.Matsumoto Y, Saito M, Saito K, Kanke Y, Watanabe Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, Kumamoto K, Ohki S, Takenoshita S. Enhanced expression of KIF4A in colorectal cancer is associated with lymph node metastasis. Oncol Lett. 15(2): 2188-2194, 2018.
11.Minamikawa K, Shibata M, Gonda K, Ujiie D, Ashizawa M, Nakajima T, Okayama H, Sakamoto W, Saito M, Momma M, Mimura M, Ohki S, Shimura T, Ohto H, Takenoshita S, Kono K. IL-17 and VEGF are significantly associated with disease progression involving systemic inflammation in patients with gastric and colorectal cancers. Ann. Cancer Res. Ther. Vol. 25, No. 2, pp. 67-76, 2017.
12.Mimura K, Teh JL, Okayama H, Shiraishi K, Kua LF, Koh V, Smoot DT, Ashktorab H, Oike T, Suzuki Y, Fazreen Z, Asuncion BR, Shabbir A, Yong WP, So J, Soong R, Kono K. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 109(1): 43-53, 2018.
13.Minamikawa K, Okumura A, Kokudo N, Kono K. Regulation on introducing process of the highly difficult new medical technologies: A survey on the current status of practice guidelines in Japan and overseas. Biosci Trends. 12(6): 560-568,2018
14.Nakajima T, Okayama H, Ashizawa M, Noda M, Aoto K, Saito M, Monma T, Ohki S, Shibata M, Takenoshita S, Kono K. Augmentation of antibody-dependent cellular cytotoxicity with defucosylated monoclonal antibodies in patients with GI-tract cancer. Oncol Lett. 15(2): 2604-2610, 2018.
15.Noda M, Okayama H, Kofunato Y, Chida S, Saito K, Tada T, Ashizawa M, Nakajima T, Aoto K, Kikuchi T, Sakamoto W, Endo H, Fujita S, Saito M, Momma T, Ohki S, Kono K. Prognostic role of FUT8 expression in relation to p53 status in stage II and III colorectal cancer. PLoS One. 13(7): e0200315, 2018.
16.Noda M, Okayama H, Tachibana K, Sakamoto W, Saito K, Thar Min AK, Ashizawa M, Nakajima T, Aoto K, Momma T, Katakura K, Ohki S, Kono K. Glycosyltransferase Gene Expression Identifies a Poor Prognostic Colorectal Cancer Subtype Associated with Mismatch Repair Deficiency and Incomplete Glycan Synthesis. Clin Cancer Res. 24(18): 4468-4481, 2018.
17.Nohara K, Yamada K, Yamada L, Hagiwara T, Igari T, Yokoi C, Soma D, Yamashita S, Dohi T, Kawamura YI. Expression of kallikrein-related peptidase 13 is associated with poor prognosis in esophageal squamous cell carcinoma. Gen Thorac Cardiovasc Surg. 66(6): 351-357, 2018.
18.Okonogi N, Suzuki Y, Sato H, Oike T, Yoshimoto Y, Mimura K, Noda SE, Okamoto M, Tamaki T, Morokoshi Y, Hasegawa S, Ohgaki H, Yokoo H, Nakano T. Combination Therapy of Intravenously Injected Microglia and Radiation Therapy Prolongs Survival in a Rat Model of Spontaneous Malignant Glioma. Int J Radiat Oncol Biol Phys.102(3): 601-608, 2018.
19.Osanai-Sasakawa A, Hosomi K, Sumitomo Y, Takizawa T, Tomura-Suruki S, Imaizumi M, Kasai N, Poh TW, Yamano K, Yong WP, Kono K, Nakamura S, Ishii T, Nakai R. An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models. Am J Cancer Res. 8(8): 1499-1513, 2018.
20.Saito M, Goto A, Abe N, Saito K, Maeda D, Ohtake T, Murakami Y, Takenoshita S. Decreased expression of CADM1 and CADM4 are associated with advanced stage breast cancer. Oncol Lett. 15(2): 2401-2406, 2018.
21.Saito M, Saito K, Nakano H, Kikuchu T, Okayama H, Fujita S, Endo H, Sakamoto H, Momma T, Ohki S, Kono K. Annexin A1 is upregulated in p53-positive gastric cancer. Ann. Cancer Res. Ther. 26(1): 26-30, 2018.
22.Saito M, Saito K, Shiraishi K, Maeda D, Suzuki H, Minamiya Y, Kono K, Kohno T, Goto A. Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. Mol Clin Oncol. 8(2): 310-314, 2018.
23.Sawamura Y, Ohto H, Ikeda K, Kanno T, Suzuki Y, Gonda K, Tasaki T, Nollet K.E, Takahashi H, Aota S. Impact of prestorage leucoreduction of autologous whole blood on length of hospital stay with a subgroup analysis in bilateral hip arthroplasty. Vox Sang. 2018 Jun 20. doi: 10.1111/vox.12674.
24.Shimura T, Shibata M, Gonda K, Hayase S, Sakamoto W, Okayama H, Fujita S, Saito M, Momma T, Ohki S, Kono K. Prognostic impact of preoperative lymphocyte-to-monocyte ratio in patients with colorectal cancer with special reference to myeloid-derived suppressor cells. Fukushima J Med Sci. 64(2): 64-72, 2018.
25.Shimura T, Shibata M, Gonda K, Kofunato Y, Ishigame T, Okada R, Sato N, Kimura T, Kenjo A, Marubashi S. Prognostic impact of soluble intercellular adhesion molecule-1 in hepatocellular carcinoma. Oncol Lett. 16(5): 6013-6018, 2018.
26.Shimura T, Shibata M, Gonda K, Matsumoto Y, Nakano K, Iwadate M, Suzuki S, Suzuki S. Prognostic impact of elevated preoperative C-reactive protein on patients with differentiated thyroid carcinoma. J Surg Res. 231: 338-345, 2018.
27.Shimura T, Shibata M, Gonda K, Okayama H, Saito M, Momma T, Ohki S, Kono K. Serum transthyretin level is associated with prognosis of patients with gastric cancer. J Surg Res. 227: 145-150, 2018.
28.Shimura T, Shibata M, Kofunato Y, Okada R, Ishigame T, Kimura T, Kenjo A, Marubashi S. Clinical significance of serum transthyretin level in patients with hepatocellular carcinoma. ANZ J Surg. 88(12): 1328-1332, 2018.
29.Sundar R, Rha SY, Yamaue H, Katsuda M, Kono K, Kim HS, Kim C, Mimura K, Kua LF, Yong WP. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. BMC Cancer. 18(1): 332, 2018.
30.Tan YJ, Lee YT, Yeong KY, Petersen SH, Kono K, Tan SC, Oon CE. Anticancer activities of a benzimidazole compound through sirtuin inhibition in colorectal cancer. Future Med Chem. 10(17): 2039-2057, 2018.
31.Thar Min AK, Okayama H, Saito M, Ashizawa M, Aoto K, Nakajima T, Saito K, Hayase S, Sakamoto W, Tada T, Hanayama H, Saze Z, Momma T, Ohki S, Sato Y, Motoyama S, Mimura K, Kono K. Epithelial-mesenchymal transition-converted tumor cells can induce T-cell apoptosis through upregulation of programmed death ligand 1 expression in esophageal squamous cell carcinoma. Cancer Med. 7: 3321-3330, 2018.
32.Watanabe Y, Saito M, Saito K, Matsumoto Y, Kanke Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, Ohki S, Takenoshita S. Upregulated HOXA9 expression is associated with lymph node metastasis in colorectal cancer. Oncol Lett. 15(3): 2756-2762, 2018.
②総説等
1.Kono K. Advances in cancer immunotherapy for gastroenterological malignancy. Ann Gastroenterol Surg. 2: 244-245, 2018.
2.Kono K, Mimura K, Yamada R, Ujiie D, Hayase S, Tada T, Okayama H, Thar Min AK, Shibata M, Momma T, Saze Z, Ohki S. Current status of cancer immunotherapy for esophageal squamous cell carcinoma. Esophagus. 15(Issue1): 1-9, 2018.
3.Mimura K, Yamada L, Ujiie D, Hayase S, Tada T, Hanayama H, Thar Min AK, Shibata M, Momma T, Saze Z, Ohki S, Kono K. Immunotherapy for esophageal squamous cell carcinoma : a review. Fukushima J. Med. Sci. 64(2): 46-53, 2018.
4.Okayama H, Noda M, Kono K. Aberrant glycosylation in colorectal cancer with genomic and epigenomic alterations. Oncotarget. 9(86): 35609-35610, 2018.
5.Saito M, Kono K, Kohno T. Identification of a novel therapeutic target in driver-negative non-small cell lung cancer. Transl Lung Cancer Res. 7(Suppl 3): S218-S220, 2018.
6.Saito M, Momma T, Kono K. Targeted therapy according to next generation sequencing-based panel sequencing. Fukushima J Med Sci. 64(1): 9-14, 2018.
7.Saito M, Shiraishi K, Goto A, Suzuki H, Kohno T, Kono K. Development of targeted therapy and immunotherapy for treatment of small cell lung cancer. Jpn J Clin Oncol. 48(7): 603-608, 2018.
8.Saito M, Suzuki H, Kono K, Takenoshita S, Kohno T. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surgery Today. 48(1): 1-8, 2018.
9.Shibata M, Gonda K, Shimura T, Sakurai K, Takenoshita S. SIRS, CARS and MARS in relationship to cancer cachexia and its clinical implications. Ann. Cancer Res. Ther. 26( 1): 54-59, 2018.
10.Yehya AHS, Asif M, Petersen SH, Subramaniam AV, Kono K, Majid AMSA, Oon CE. Angiogenesis: Managing the Culprits behind Tumorigenesis and Metastasis. Medicina. 54(1):8, 2018.
1.Azuhata T, Shibata M, Nakamura K, Kawano D, Terakado Y, Azuhata I, Sakurai A, Yamada T, Sugita K, Tomita R, Tsuyama Y, Tanjoh K, Azuhata S. A case of clinical complete response of colorectal liver metastasis following chemotherapy with S-1 and oxaliplatin (SOX) in combination with bevacizumab. Ann. Cancer Res. Ther. 26(2): 101-104, 2018.
2.Gonda K, Tachiya Y, Hatakeyama Y, Momma T, Tamaoki T, Maejima Y, Rokkaku Y, Saji S, Shimomura K, Kono K. Poland syndrome accompanied by internal iliac artery supply disruption sequence: a case report. J Med Case Rep. 12(1): 312, 2018.
